SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-024152
Filing Date
2022-11-10
Accepted
2022-11-10 07:12:37
Documents
81
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fnch-20220930.htm   iXBRL 10-Q 3034470
2 EX-10.1 fnch-ex10_1.htm EX-10.1 68961
3 EX-31.1 fnch-ex31_1.htm EX-31.1 22096
4 EX-31.2 fnch-ex31_2.htm EX-31.2 22420
5 EX-32.1 fnch-ex32_1.htm EX-32.1 23194
  Complete submission text file 0000950170-22-024152.txt   10528479

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fnch-20220930_def.xml EX-101.DEF 226300
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fnch-20220930_pre.xml EX-101.PRE 387194
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fnch-20220930.xsd EX-101.SCH 64451
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fnch-20220930_cal.xml EX-101.CAL 64031
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fnch-20220930_lab.xml EX-101.LAB 532161
75 EXTRACTED XBRL INSTANCE DOCUMENT fnch-20220930_htm.xml XML 1967810
Mailing Address 200 INNER BELT ROAD SOMERVILLE MA 02143
Business Address 200 INNER BELT ROAD SOMERVILLE MA 02143 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

IRS No.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40227 | Film No.: 221374909
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences